Non-insulin-dependent diabetes mellitus (NIDDM) is associated with increased cardiovascular mortality in white European and other westernized populations [1] [2] [3] [4] [5] [6] . A recent study from former East Berlin, where diabetes was a centrally registered disease, indicated that the loss of life of NIDDM patients diagnosed before age 70 years was about 30 % of the further life expectancy without diabetes [6] . Approximately 60 % of mortality is from cardiovascular or other macrovascular complications [2] . The risk factors responsible for the excessive macrovascular mortality and morbidity have not been well defined. It is thought the classical cardiovascular risk parameters, i. e. hypertension, hypercholesterolaemia, and smoking, must be involved [1, 4, [7] [8] [9] [10] , and increased urine albumin excretion has been incriminated by a number of studies [11] [12] [13] [14] [15] [16] [17] . The Diabetes Control and Complications Trial [18] and studies in NIDDM patients, have directed attention to the potential importance of metabolic control also in patients with NIDDM [8, 9, 17, 19-21]. Abnormal coagulation Diabetologia (1996Diabetologia ( ) 39: 1540Diabetologia ( -1545 Original studies
factors, endothelial proteins, platelet function, and fibrinolysis may play a role [22] .
In the Munich General Practitioner Project, a defined cohort of NIDDM patients living in the Greater Munich Area launched in 1984/1985, many potential risk factors were assessed, together with macrovascular disease [9, 16, 23] . A long-term study with 10-year follow-up was planned to evaluate factors at baseline predicting the outcome in terms of macrovascular and all-cause mortality in patients with NIDDM.
Subjects and methods
Study cohort. The Munich General Practitioner Project has been described in detail previously [9, 16, 23, 24] . Briefly, 314 patients were selected for further investigation and follow-up by a random procedure (approximately 1 in 5) from a representative sample of 1512 patients with NIDDM below age 76 years as seen in 22 non-specialized, primary medical care practices, at the beginning of the project in 1984/1985. Twenty-four of these patients declined more complex investigations at baseline, therefore, 290 were enrolled at the start of the study (103 men, 187 women, median aged 65 years, interquartile range 59-70 years, duration of diabetes 0-21 years with a median of 8 years). The characteristics of the baseline group (57 % treated with oral agents, 9 % with insulin, the rest on diet alone) with a median HbA 1c of 7.9 % have been published [16, 23] . This group exhibited similarities to NIDDM patients of the former German Democratic Republic where central registration of all diabetic subjects was compulsory [25] . To ensure long-term observation, the following exclusion criteria have been used in the project at entry: age over 75 years, serum creatinine over 177 m mol/l, apparent malignancy, advanced cardiovascular complications (gangrene, amputations, myocardial infarction during the preceding year, decompensated cardiac insufficiency or cerebral infarction). Diagnosis of NIDDM was made according to World Health Organisation (WHO) criteria [26] by the local primary care physician and informed consent was obtained from each patient prior to the study, which was approved by the local ethical committee and performed in accordance with the principles of the Declaration of Helsinki.
Evaluation of risk markers and macrovascular disease was performed at baseline. Apart from a complete history and physical examination, blood pressure was measured on both arms under resting conditions three times at 2-min intervals with the lowest reading being taken for the classification of hypertension according to the WHO criteria (> 160/95 mm Hg). Ischaemic heart disease was assessed by a 12-lead ECG using the Whitehall criteria [27] of the Minnesota coding system (criteria: I 1-3, IV 1-3, V 1-2, and VII 1). Ectopic beats, sinus tachycardia or bradycardia were not considered in the rating system. Peripheral vascular disease was evaluated by the determination of blood pressure at all four extremities, i. e. at the ankle level of the lower limbs and at the upper arms using an ultrasound-Doppler device. This examination was performed after a rest of 15 min, and a leg-arm difference of less than 10 mm Hg was considered as a pathological result [28] . To exclude false-negative results due to medial calcification of the Moenckeberg type, a Doppler-signal wave form was also recorded. Medial calcification was assumed when the normally triphasic Doppler-signal wave form was non-functionally monophasic, widened and with reduced amplitude despite a normal Doppler index [29] . For the assessment of extracranial cerebrovascular disease, a directional continuous wave ultrasound-Doppler examination of the carotid arteries was carried out. Stenoses of more than 50 % and/or obliterations were defined as carotid artery disease. Finally, relative body weight was recorded as body mass index (kg/m 2 ). Patients' knowledge about diabetes and its appropriate treatment was assessed by a multiple choice questionnaire and rated as the number of correct answers out of the total of 21 questions.
The first morning urine sample was examined for albuminuria by means of a radioimmunoassay (Pharmacia, Freiburg, Germany) with a detection threshold of 0.4 mg/l. The urine sample was also screened for glycosuria and for urinary tract infection, i. e. bacteriuria, leucocyturia, erythrocyturia. Venous blood was drawn after an overnight fast without stasis and vonWillebrand-factor protein (vWF protein) was determined in plasma by quantitative immune electrophoresis [30] and expressed as percentage of a standard reference (100 %). Blood glucose and HbA 1c were assayed in capillary blood, and total cholesterol, HDL-cholesterol, triglycerides, creatinine, and b 2 -microglobulin in serum by standard procedures [31] .
Follow-up and definition of outcome. Follow-up investigations have been performed 3 and 5 years after the baseline examination and results published previously [9, 16] . The present study was designed as a follow-up on 10-year (macrovascular) mortality. In spring 1995, all participants were contacted and data of 92.5 % of the original cohort of 290 patients at baseline could be obtained for analysis through the patients themselves, their primary care physicians or the local administration authorities. Only 22 patients were lost to follow-up but their baseline characteristics did not differ from the rest of the cohort. For patients who had died, cause of death was assessed from death certificates, hospital records and autopsy reports by means of a standardized questionnaire. Of the 103 deceased patients 27 were examined by autopsy, 78 died in hospital. Causes of death were classified as clearly due to macrovascular disease, or confirmed other reasons or unknown. Criteria for macrovascular death (cardiovascular and/or cerebrovascular in all instances except one ruptured aneurysm of the abdominal aorta) included confirmation of the diagnosis on the death certificate or the hospital record or an autopsy report confirming the presence of macrovascular disease as cause of death and the absence of non-macrovascular disease that could explain death.
Statistical analysis
Statistical analysis was done using the SPSS/PC package [32] . Results are given as median values + interquartile ranges or as percentages. Differences were assessed by chi-square or Wilcoxon test as appropriate. Comparisons between survivors and deceased patients or deceased patients from macrovascular disease, respectively, were corrected for age by using logistic, regression analysis with age as a covariate. Since lossto-follow-up was small (approximately 7 %), stepwise logistic regression analysis was performed using all variables significantly different in univariate analysis together with the main markers of the metabolic syndrome, hypertension, dyslipoproteinaemia, and body mass index, and with macrovascular death or all-cause mortality as the outcome [33] . This analysis was done with and without inclusion of ischaemic heart disease, peripheral vascular disease, and carotid artery disease present at baseline to evaluate the impact of pre-existing macrovascular disease. In addition, a multiple logistic regression analysis was also performed, including only the main markers of the metabolic syndrome, hypertension, dyslipidaemia, body mass index and HbA 1c , together with age. For modelling, dyslipidaemia was defined as cholesterol over 6.5 mmol/l or HDL-cholesterol under 0.9 mmol/l or triglycerides over 2.6 mmol/l.
Finally, percentage of macrovascular mortality in subgroups with and without preexisting macrovascular disease were computed in relation to tertiles of HbA 1c and vWF-protein at baseline.
Results
Status and causes of death. Over the 10-year period of follow-up, 103 (38.5 %) of the 268 re-investigated patients of the original cohort (92.5 % ascertainment) were deceased, 58 (56.3 %) of whom clearly had died from macrovascular causes and 33 (32 %) from confirmed non-macrovascular reasons. In 12 (11.7 %) of all deaths, the cause of death could not be classified.
Baseline factors and outcome. Table 1 depicts the clinical baseline characteristics of the 165 patients alive, the 103 deaths and the 58 macrovascular deaths. Patients with macrovascular deaths and all-cause deaths were significantly older than survivors at the beginning of the study in 1984/1985 (median plus interquartile ranges: 68, 64-72 years vs 67, 64-72 years vs 63, 56-69 years, p < 0.003). Age-corrected comparison indicated that deceased patients had a similar body weight and known duration of diabetes, but significantly more ischaemic heart disease, carotid artery disease, and peripheral vascular disease at baseline and showed a significantly inferior knowledge about diabetes and its treatment. As might be expected differences were more marked for macrovascular deaths than for all-cause deaths compared to the survivors. No significant differences were found as to gender, antidiabetic therapy at baseline, the use of common antihypertensive and coronary drugs, e. g. beta blockers, Ca-antagonists, nitrates, platelet aggregation inhibitors and smoking. The prevalence of the various antihypertensive and coronary drugs, and for active smoking at baseline 1984/1985, was low and from 3.5 % for antiplatelet drugs to 16 % for active smoking. 
Multivariate analysis.
Stepwise logistic regression analysis of factors influencing macrovascular death as outcome indicated age, HbA 1c and vWF protein as significant independent determinants of macrovascular death (Table 3) . When co-existing macrovascular disease at baseline (ischaemic heart, carotid artery, and peripheral vascular disease) were incorporated into the model, again HbA 1c , vWF protein, and in addition carotid artery disease emerged as significant predictors of macrovascular mortality besides age (Table 3 ). As to all-cause deaths as outcome, the pattern of risk variables in stepwise logistic regression analysis was less clear, but again included age (p = 0.004); vWF protein (p = 0.005), carotid artery disease (p = 0.008), glycaemic control as measured by fasting blood glucose (p = 0.04), b 2 -microglobulin (p = 0.05) and urinary albumin excretion (p = 0.05) as significant predictors, in the two models applied.
Restricting multiple regression analysis for macrovascular death as outcome to the main markers of the metabolic syndrome at baseline (Table 4) indicated that only HbA 1c -besides age -was of significant importance. Finally, Figure 1 demonstrates frequencies of macrovascular mortality with higher tertiles of HbA 1c and of vWF protein. As can be seen, there is a steep increase of macrovascular mortality with higher tertiles, even when pre-existing macrovascular disease was taken into account.
Discussion
This is a 10-year prospective study to evaluateamong most of the presently known or suspected risk factors -significant determinants of macrovascular and all-cause mortality in a cohort of well-characterised NIDDM patients. By stepwise logistic regression analysis it showed that glycaemic control as measured by HbA 1c and circulating concentrations of the endothelial protein, vWF protein, besides age, were risk factors for the macrovascular mortality outcome in NIDDM patients. These findings persisted, even when co-existing macrovascular disease at baseline, i. e. coronary, carotid, and peripheral vascular disease were taken into account which all had been assessed by appropriate techniques at entry. Applying this approach, however, it was demonstrated that together with HbA 1c and vWF protein the presence of carotid artery disease emerged as a significant independent determinant of macrovascular death. Similarly, the independent effect of HbA 1c and vWF protein, was apparent with and without considering macrovascular disease at entry when frequency of macrovascular deaths were computed in relation to tertiles of HbA 1c and vWF protein at baseline (Fig. 1) . When the main markers of the metabolic syndrome were incorporated into multiple logistic analysis, HbA 1c and age remained the major predictors of macrovascular death. In terms of all-cause mortality, results of multivariate analysis were less clear cut, but were in keeping with the observations, obtained for macrovascular deaths.
Debate has recently been intensified as to how much glycaemic control matters not only for the outcome of patients with IDDM, but also for those with NIDDM. So far, reports from two Scandinavian studies in 1994 and 1995 [19, 20] have provided evidence that long-term cardiovascular mortality of NIDDM patients may be significantly associated with increasing tertiles of the baseline HbA 1c or fasting blood glucose. The present study has shown that HbA 1c was predictive for macrovascular mortality in a multivariate analysis. Final proof for the impact of glycaemic control on the macrovascular or overall outcome of NIDDM patients, however, has to be awaited from specifically planned intervention studies, e. g. the UKPDS [34] . Serum vWF protein was found to be a risk factor for macrovascular mortality. Previously, vWF protein has predominantly been discussed in relation to diabetic microangiopathy [22, 35] . On the other hand, vWF protein has been shown of correlate closely with platelet aggregation in diabetic patients and to precede structural vascular changes in experimental and human diabetes [35, 36] . VWF protein is essential for normal platelet adhesion to the vessel wall and is mainly produced by endothelial cells [22] . Increased circulating levels of vWF protein have been thought to reflect endothelial damage and signify an active crosstalk of the endothelium with platelets, especially when activation molecules such as CD62 are expressed on the platelet surface, as is quite often the case in diabetes [22] . In the present study, vWF protein was associated with macrovascular mortality both in the presence and absence of established macrovascular disease at entry into the study.
Surprisingly little influence of the classical cardiovascular risk factors, i. e. smoking, hypertension, and dyslipidaemia including hypercholesterolaemia, was seen on the 10-year outcome in the Munich General Practitioner Project. This may have specific reasons, since the prevalence of smoking was only 16 % at baseline, and 46 % of all subjects were already under treatment with antihypertensive drugs at entry to the study and 75 % had a blood pressure 170/95 mm Hg or less at recruitment ( Table 2) . Total cholesterol and HDLcholesterol were similar to the general population at median age 65 in Germany and 75 % of all patients had a total cholesterol of less than 7.0 mmol/l (Table 2). Unfortunately, neither small dense LDL nor lipoprotein (a) were measured. On the other hand other long-term studies in NIDDM have also recently failed to demonstrate a significant impact of blood pressure [17] , lipids [8] , or smoking [4, 8] on mortality, so there is uncertainty as to the importance of these factors in NIDDM populations. However, these studies have been moderately small, and they do not disprove the influence of the classical cardiovascular factors in NIDDM. These were shown to be operative when non-diabetic and diabetic populations were compared, e. g. in the Framingham [37] Multiple Risk Factor Intervention Trial [1] , and in one of the Scandinavian studies [10] . The present study indicates a role for HbA 1c and vWF protein in determining macrovascular mortality in NIDDM patients. 
